The effect of HPV analysis on the ASC/SIL ratio which is one of the quality control criteria for PAP smears

Year 2021, , 72 - 74, 29.01.2021

Ipek Erbarut Seven

https://doi.org/10.5472/marumj.869541

Abstract

Objective: The high number of smear tests has a workload on pathologists/cytopathologists, which raises the concern for the quality
of diagnoses. The application of high-risk human papillomavirus (hr-HPV) analyses with the PAP smear has begun to contribute to
the clinical practice. In this study, we aimed to show the effect of hr-HPV analysis on the results of PAP smear via atypical squamous
cell/squamous intraepithelial lesion (ASC/SIL) ratio on the quality standards.
Material and Methods: A total of 12799 cervical cytology reports, between 2014-2016, from the Pathology Department of Marmara
University Hospital, were included. Between November 2014 and May 2016, hr-HPV analysis was performed on a total of 4307 cases
with Hologic Aptima HPV™, USA. Smear diagnoses before and after the start of the HPV test application were recorded.
Results: The cytology diagnoses, during when hr-HPV screening was not performed, were: negative for intraepithelial lesion or
malignancy (NILM) 99.4%, atypical squamous cells of undetermined significance (ASCUS) 0.6%, low-grade squamous intraepithelial
lesion (LSIL) 0.2%, ASC-H 0.04%, and high-grade squamous intraepithelial lesion (HSIL) 0.13%. The cytology diagnoses that were
evaluated with HPV test were as follows: NILM 93.67%, ASCUS 2.31%, LSIL 2.82%, ASC-H 0.3%, and HSIL 0.91%. ASC/SIL ratio has
been dropped from 1.9 to 0.7 after the initiation of hr-HPV use.
Conclusion: During the period without hr-HPV analysis, the ASC/SIL ratio was 1.9. Later with the initiation of hr-HPV screening
this ratio decreased to 0.7. This shows that knowing HPV test results affects and improves the quality of the laboratory diagnoses.

Keywords

ASC/SIL ratio, quality, PAP smear, HPV analysis

References

• Felix JC, Lacey MJ, Miller JD, Lenhart GM, Spitzer M, Kulkarni R. The clinical and economic benefits of co-testing versus primary HPV testing for cervical cancer screening: A modeling analysis. J Women’s Health 2016;25:606-16.doi: 10.1089/jwh.2015.5708
• Wright TC Jr, Stoler MH, Aslam S, Behrens CM. Knowledge of patients’ human papillomavirus status at the time of cytologic review significantly affects the performance of cervical cytology in the ATHENA Study. Am J Clin Pathol 2016;146:391-8.doi: 10.1093/ajcp/aqw125
• Juskevicius R, Zou KH, Cibas ES. An analysis of factors that influence the ASCUS/SIL ratio of pathologists. Am J Clin Pathol 2001;116:331-5.doi: 10.1309/0BL4-6H9V-DQVVUGXR
• Alessandra F. Nascimento ESC. The ASC/SIL ratio for cytopathologists as a quality control measure: A follow-up study. Am J Clin Pathol 2007;128:653-6. doi: 10.1309/ APTVNLP1P0X00CUQ
• Nayar R, Wilbur D. (Eds) The Bethesda System for reporting cervical cytology. Switzerland: Springer, 2015. ISBN 978-3- 319-11073-8. doi: 10.1007/978-3-319-11074-5
• Kurman RJ. Specimen adequacy. In: Solomon D, ed. The Bethesda System for Reporting Cervical/Vaginal Cytologic Diagnoses. New York, NY: Springer – Verlag, 1994.
• Rebolj JR M, Denton K, Tidy J, et al. Primary cervical screening with high risk human papillomavirus testing: observational study. BMJ 2019; 6;364:l240. doi: 10.1136/bmj.l240
• Yang J, Nolte FS, Chajewski OS, et al. Cytology and high risk HPV testing in cervical cancer screening program: Outcome of 3-year follow-up in an academic institute. Diagn Cytopathol 2018;46:22-7. doi: 10.1002/dc.23843
• Perkins RB, Guido RS, Castle PE, et al. 2019 ASCCP Risk- Based Management Consensus Guidelines Committee. 2019 ASCCP Risk-Based Management Consensus Guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis 2020;24:102-31. doi:10.1097/ LGT.000.000.0000000525
• Benoy IH, Broeck DV, Ruymbeke MJ, et al. Prior knowledge of HPV status improves detection of CIN2 by cytology screening. Am J Obstet Gynecol 2011;205:1-7.doi: 10.1016/j. ajog.2011.06.101
• Renshaw AA, Deschênes M, Auger M. ASC/SIL ratio for cytotechnologists: A surrogate marker of screening sensitivity. Am J Clin Pathol 2009;131:776-81. doi: 10.1309/ AJCPXANG59GPHJNU
• Commission on Laboratory Accreditation Laboratory Accreditation Program. Cytopathology checklist. CYP07650 Available at https://elsscaporg/elss/ShowProperty?nodePath=/ UCMCON/Contribution%20Folders/DctmContent/ education/OnlineCourseContent/2017/LAP-